BiotechTube
Manifold Bio

Manifold Bio

Cambridge, United States· Est.
manifold.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45.4M

Overview

Manifold Bio is a private, preclinical-stage biotech based in Cambridge, MA, founded in 2019. The company has developed a unique platform that integrates AI-guided protein design with direct, high-throughput in vivo testing to engineer biologics with precise tissue-targeting properties. Its initial pipeline focuses on CNS-targeted therapies for Alzheimer's and Parkinson's diseases, with a broader vision to build a 'virtual organism' predictive model. The company is backed by notable investors and has entered a strategic collaboration with Roche.

Alzheimer's DiseaseParkinson's DiseaseCardiometabolic Disease

Technology Platform

High-throughput in vivo (HTV) discovery engine combining AI-guided protein design with massively multiplexed in vivo screening via molecular barcoding (mCodes).

Funding History

2
Total raised:$45.4M
Series A$40M
Seed$5.4M

Opportunities

The platform addresses the critical bottleneck of tissue-specific drug delivery, particularly for the brain, opening vast markets in neurology and beyond.
Strategic partnerships, like the one with Roche, provide non-dilutive funding, validation, and a path to expand the technology's application across multiple therapeutic areas and modalities.

Risk Factors

The novel, integrated platform is unproven in clinical development and faces significant technical risks in scaling and translation.
The company operates in the highly competitive and capital-intensive AI-biotech space, with execution risk in advancing its internal pipeline and maintaining a technological edge.

Competitive Landscape

Manifold competes with other AI-native drug discovery companies (e.g., Absci, Generate Biomedicines) and biotechs focused on tissue-specific delivery (e.g., Denali Therapeutics). Its key differentiator is the direct generation of high-throughput in vivo data to train its AI models, a approach less common than purely in silico or in vitro-focused platforms.

More companies in AI / Machine Learning →More companies in United States →